Aberrant chromatin remodeling is involved in the pathogenesis of Huntington's disease (HD) but the mechanism is not known. Herein, we report that mutant huntingtin (mtHtt) induces the transcription of alpha thalassemia/mental retardation X linked (ATRX), an ATPase/helicase and SWI/SNF-like chromatin remodeling protein via Cdx-2 activation. ATRX expression was elevated in both a cell line model and transgenic model of HD, and Cdx-2 occupancy of the ATRX promoter was increased in HD. Induction of ATRX expanded the size of promyelocytic leukemia nuclear body (PML-NB) and increased trimethylation of H3K9 (H3K9me3) and condensation of pericentromeric heterochromatin, while knockdown of ATRX decreased PML-NB and H3K9me3 levels. Knockdown of ATRX/dXNP improved the hatch rate of fly embryos expressing mtHtt (Q127). ATRX/dXNP overexpression exacerbated eye degeneration of eye-specific mtHtt (Q127) expressing flies. Our findings suggest that transcriptional alteration of ATRX by mtHtt is involved in pericentromeric heterochromatin condensation and contributes to the pathogenesis of HD.
Huntington's disease (HD) is an incurable and fatal autosomal dominant neurodegenerative disorder of mid-life onset characterized by chorea and progressive cognitive decline. 1 HD is caused by expanded CAG repeats coding for glutamine (Q) in the exon 1 of the Huntingtin (Htt) gene. 2 One mechanism by which mutant Htt (mtHtt) contributes to neurodegeneration is through transcriptional dysregulation and chromatin remodeling. [3] [4] [5] [6] Aberrant nucleosomal dynamics have recently been implicated in the pathogenesis of HD but the exact role of chromatin remodeling remains to be elucidated.
Chromatin remodeling complexes modulate the structure of nucleosomes around the transcription initiation site and define its accessibility to the transcription machinery in an adenosine triphosphate (ATP) -dependent manner. 7 Alpha thalassemia/ mental retardation X linked (ATRX) is a DNA-dependent ATPase/helicase belonging to the Rad54-like subfamily of SWI/SNF chromatin remodeling proteins. 8, 9 Mutations of ATRX are directly linked to ATR-X syndrome, a rare X-linked mental retardation disorder accompanied with learning difficulties, characteristic facial appearance, anemia, and genomic instability. 10, 11 Transgenic expression of ATRX results in growth retardation and neural tube defects, suggesting that normal development of the cortex are susceptible to ATRX dosage. 12 ATRX collaborates with methyl-CpG-binding protein 2 and Daxx and disruption of these interactions may cause transcriptional deregulation and pathological changes that contribute to mental retardation. [13] [14] [15] In addition, the loss of ATRX leads to genomic instability and impaired corticogenesis. 11, 16 ATRX is an epigenetic modulator necessary for cell survival during early neuronal differentiation and its abnormal induction or deficiency leads to neuronal degeneration, but the mechanisms responsible are largely unknown.
Given that deregulation of nucleosomal dynamics contributes to the HD pathogenesis and that ATRX expression is elevated in peripheral blood of HD, it is reasonable to suggest that ATRX could have a role in chromatin remodeling and neurodegeneration in HD. Accordingly, in order to determine how ATRX induction is linked to chromatin remodeling and the neurodegenerative process, we investigated transcriptional mechanisms of ATRX gene expression in HD. As ATRX null mice do not survive beyond birth, we crossed mtHtt (Q127) and ATRX/dXNP transgenic flies to examine the effects of ATRX depletion on embryonic development and eye phenotype in the context of triplet repeat expansion.
Results
ATRX is elevated in a cell line and an animal model of HD. In order to investigate whether ATRX is linked to histone remodeling in the pathogenesis of HD, we first examined the protein and the immunoreactivity of ATRX in a striatal cell line model and an animal (R6/2) of HD 17 ( Figure 1 and Supplementary Figure 1) . The immortalized striatal cells were previously established from STHdhQ7/Q7 (wild type) and homozygous mutant STHdhQ111/Q111 (Q111/Q111) knock-in mouse embryos. 18 The level of ATRX protein was significantly increased in STHdhQ111/Q111 compared with STHdhQ7/Q7 (Q7/Q7) control cells, as shown by western blot analysis (Figure 1a) . Consistent with western blot data, ATRX immunoreactivity was elevated, and punctate ATRX positive structures were markedly increased in the nucleus of Figure 1a) . We next determined the distribution of ATRX immunoreactivity in striatal neurons R6/2 mice using confocal microscopy and image analysis. We found that ATRX immunoreactivity was increased, and that the majority of ATRX immunoreactivity was colocalized with trimethylation of H3K9 (H3K9me3) in prominent clusters of pericentromeric heterochromatin (chromocenters) in R6/2 mice (Figure 1c) . ATRX immunoreactivity also colocalized with HP1a in nuclear foci of R6/2 mice that were spatially different and distinguishable from WT mice (Figure 1d and Supplementary Figure 1b) . To determine whether ATRX was affected in vivo, we examined ATRX mRNA and protein levels in striatal neurons stably expressing GFP or the mutant huntingtin (mtHtt) GFP-fusion protein (GFP-Q79) and found that ATRX levels were increased in mutant cells compared with the control cells (Figures 1e and f) .
Cdx2 drives ATRX promoter activity. To determine how ATRX is activated at the transcriptional level, we cloned the promoter of human ATRX into a luciferase vector (pGL4.14). We ran TFSEARCH software (Kyoto University, Japan) with the promoter sequence of ATRX and found transcription factor-binding elements for Cdx, Sp1/3, CREB, and GATA2-binding elements (Figure 2a ). To determine which transcription factors modulate the transcriptional activation of ATRX, we constructed variants of the ATRX promoter region (ATRX, À548/ þ 101; ATRX, À438/ þ 101; ATRX, À248/ þ 101). We co-transfected Sp1, Sp3, Cdx1, and Cdx2 expression vectors with the ATRX promoter plasmids and measured luciferase activity. Among four factors, Cdx2 showed the strongest transcriptional activity of the ATRX promoter ( Figure 2b ). It is well known that Cdx1 and Cdx2 transcription factors are important regulators of intestinal epithelial cell differentiation, apoptosis, and proliferation but its function in the central nervous system has not been investigated. While two potential Cdx-binding sites emerged, our data demonstrates that the proximal site functions as an important cis-element within the ATRX promoter ( Table 1) .
Consistent with our earlier finding that mtHtt could increase Atrx protein levels, ATRX promoter activity was similarly increased in cells expressing mtHtt (Q103) compared with the control cell lines (GFP and GFP-27) (Figure 3a) . To verify the role of Cdx2 as a transcriptional activator over the proximal region of Cdx-binding site in the ATRX promoter, we constructed a deletion mutant for the predicted Cdx-binding site using site-directed mutagenesis ( Figure 3b ). As a template plasmid, the ATRX (À438/ þ 101) promoter variant was used. The mutant ATRX promoter (Cdx-binding element deletion) showed a basal promoter activity close to plasmid (pGL4.14) control levels ( Figure 3b ). As we expected, the deletion of Cdx2-binding site also abrogated the mtHttinduced promoter activity of the ATRX gene (Figure 3c ). Thus, our data indicates for the first time that Cdx2 is activated by mtHtt in the central nervous system and that it regulates mtHtt-mediated ATRX transcription.
ATRX modulates promyelocytic leukemia-nuclear bodies (PML-NBs) and heterochromatin condensation. ATRX is localized to pericentromeric heterochromatin and can physically interact with proteins that reside within heterochromatin including HP1. 19 The ATRX protein also localizes to PML-NBs that may have a role in transcription regulation during the neurodegenerative process. 20 To address how ATRX contributes to PML-NB formation and chromatin remodeling, we overexpressed GFP-ATRX fusion protein in striatal cells and measured PML-NB and H3K9me3 immunoreactivities and levels. PML-positive small nuclear speckles were present in Q7/Q7 cells (Figure 4a ). Overexpression of ATRX increased the size of PML-NBs (Figures 4a and b) . In contrast, knockdown of ATRX by siRNA reduced the number of PML-NBs (Figure 4c ). Overexpression of ATRX was also associated with increased H3K9me3 immunoreactivity within the nuclei of Q7/Q7 cells (Figure 4d ) that colocalized with ATRX (Figure 4d ). Both the N-terminal and C-terminal domains of ATRX were involved in the hypertrimethylation of H3K9 and heterochromatin condensation in human neuroblastoma cells ( Supplementary  Figure 3a) . Interestingly, overexpression of the C-terminal helicase domain of ATRX, including NLS (GFP-ATRX NLS1204-2492), resulted in abnormal heterochromatin condensation and nuclear damage in Q7/Q7 and Q111/ Q111 striatal cells (Supplementary Figure 3b) . In contrast, knockdown of ATRX reduced the H3K9me3 foci and pericentromeric nuclear condensation in Q111/111 and Q7/ Q7 cells (Supplementary Figure 4) . Western analysis showed ATRX/dXNP is implicated in mtHtt-mediated toxicity. ATRX knockout mice are lethal and CNS-restricted knockout animals die at birth making it difficult to study the role of ATRX in HD in this model. To further define the role of ATRX in HD, we used a Drosophila model of mtHtt-mediated toxicity ( Figure 5 ). It has previously been shown that mtHtt-induced neurodegeneration is mimicked in Drosophila with a GAL4/UAS system and a transgene expressing 127 consecutive glutamines (127Q). 21 The genetic cross with a line that expresses GAL4/UASpoly127Q under the control of the elav promoter led to a significant (35%) reduction of hatching rate (Figure 5a ). ATRX/dXNP knockdown (XNP C1 / þ ) improved the hatching rate affected by mtHtt (127Q). mtHtt (127Q) expression markedly deformed the fly embryo and ATRX/dXNP knockdown (XNP C1 / þ ) significantly reduced the number of deformed embryos (Figures 5b and c) . We also established a line that expresses GAL4 under the control of the glass multimer repeat promoter that resulted in the expression of 127Q in all cells of the retina and led to eye-specific degeneration (Figure 5d ). To further investigate the role of ATRX/dXNP in mtHtt-mediated toxicity, we crossed the GMRGAL4/UAS-127Q flies with line EP635, which carries a P(EP)-element insertion þ 20 bp from transcription site of ATRX/dXNP. The P(EP) insertion resulted in increased ATRX/dXNP expression in the presence of GAL4. As shown in Figure 5d , external eye pigmentation and the regular array of ommatidia were disrupted by mtHtt (127Q). The double expression of ATRX/dXNP exacerbated mtHtt (127Q)-mediated degeneration with complete loss of eye pigmentation. 22, 23 Flies that only overexpressed ATRX/dXNP resulted in no significant loss of eye pigmentation and minor disruption in the regular array of ommatidia (Figure 5d ).
Discussion
ATRX is known to be crucial for normal development and organization of the central nervous system. Overexpression of ATRX in transgenic mice leads to craniofacial anomalies, seizures, and behavioral changes. 12 It has been reported that ATRX expression levels are elevated in the white blood cells of presymptomatic (1.6-fold) and symptomatic HD (2-fold) patients compared with the controls. 24 Given that deregulation of nucleosomal dynamics contributes to the HD pathogenesis and that ATRX expression is elevated in the peripheral blood of HD, it is reasonable to suggest that ATRX could have a role in chromatin remodeling and neurodegeneration in HD. Indeed, we found that ATRX is transcriptionally induced by mtHtt through activation of Cdx2. Our ChIP assays confirmed that the preferential binding of Cdx2 to the ATRX promoter is markedly increased in HD (R6/2) and that Cdx2 overexpression directly regulates the expression of ATRX. Increased ATRX expression in turn leads to PML-NB expansion and increased H3K9me3. 20 In contrast, Cdx2 knockdown using shRNA leads to reduced ATRX and H3K9me3 levels. Cdx2 knockdown also abrogates the mtHtt-induced promoter activity of the ATRX gene. Our data indicate that activation of Cdx2 by mtHtt is closely linked to expression of the ATRX gene. DNA occupancy by both Sp1 and Sp3 in the promoter region indicate that Sp3 might also be involved in the transcriptional activation of ATRX in HD. Given the presence of a CREB-binding site in the proximal 5 0 -UTR promoter region of the ATRX gene, it is likely that CREB may also participate in the transcriptional regulation of ATRX.
Knockdown of ATRX reduced the formation of PML-NBs and decreased heterochromatin condensation by reducing H3K9me3 levels in striatal cells. These results suggest that heterochromatin remodeling in striatal cells is driven by ATRX under neurodegenerative conditions. 19 Interestingly, both the N-terminal ATRX-Dnmt3-Dnmt3L (ADD) domain and the C-terminal ATPase/helicase domain of ATRX modulated the dynamics of pericentromeric heterochromatin by increasing H3K9me3 levels at its target loci and ultimately, to nuclear damage in striatal cells. 15 These findings suggest that ATRX facilitates the pathological heterochromatin condensation and triggers the cascade of events leading to neuronal degeneration. 12 A recent study confirms that the ADD domain of ATRX interacts with histone H3 tails that are trimethylated at lysine 9. 25 To further examine whether ATRX directly contributes to the pathological process in HD, we developed a Drosophila model of ATRX/dXNP and characterized its physiological effects by crossing ATRX/dXNP and mtHtt (127Q) flies. We found that knockdown of ATRX increased the hatching rate and reduced egg deformations caused by mtHtt (127Q). Moreover, overexpression of ATRX/dXNP exacerbated eye degeneration in the HD fly. 22, 23 In contrast, our results show that, in part, the deformations within the fly egg and the degeneration of fly eyes are associated with mtHtt, and the pathological phenomena are mediated by gain of function of ATRX. Despite our demonstration of linking ATRX to the pathogenesis of HD via the formation of heterochromatin condensation and PML-NBs formation, the identification of ATRX targets in HD remains to be determined with a high priority. Taken together, the present study validates the contribution of ATRX to HD pathogenesis through epigenetic modulation of heterochromatin condensation ( Figure 6 ). ATRX participates in organizing the structure of pericentromeric heterochromatin by elevating trimethylated histone H3K9 levels in striatal cells. Our findings suggests that ATRX-mediated epigenetic modifications contribute significantly to pathogenesis of neurodegeneration in HD and that neuronal ATRX levels may be an indicator of aberrant chromatin remodeling in neurological disorders.
Materials and Methods
Plasmids and cell culture. pcDNA3/GFP-ATRX (1-745), ATRX (1201-2491), and ATRX (NLS1916-2492) were generously provided from Dr. Bird, 15 and pcDNA3-Cdx1 and Cdx2 constructs were from Dr. Iovanna. 26 STHdh Q7/7 (wild type) and STHdh Q111/111 (HD knock-in striatal cell line expresses mtHtt at endogenous level), were generously provided from Dr. MacDonald. 18 SH-SY5Y were maintained and used for ATRX promoter assay.
Fly (Drosophila) model of HD (127Q) and ATRX/dXNP. Flies were maintained on a standard mixture of corn meal, yeast, and agar at room temperature. The UAS-127Q and GMR-GAL4 flies were described previously. The EP635 flies were also described previously. 22, 23 By imprecise excision of a Pelement in the EP635 line, we generated XNP C1 , which has deletion of 1065 bp, removing the first exon, including the translational start site of ATRX/XNP.
Analysis of Drosophila development. Fifty embryos of each genotype were placed on grape juice agar plates. After incubation for 2 days at 25 1C, the number of hatched larvae was counted to determine embryonic lethality. The experiment was repeated eight times (n ¼ 400), and statistically analyzed by a Student's t-test. To visualize developing embryos, Hoechst 33 258 staining was performed. Briefly, embryos were collected for 16 h at 25 1C, and dechorionated in 50% bleach for 3 min. The dechorionated embryos were fixed in 4% paraformaldehyde with heptane for 20 min and devitellinized with methanol. After several washes with PBT (PBS with 0.1% Tween 20), the embryos were incubated in PBT with Hoechst 33 258 for 5 min at 25 1C. The samples were examined under an Axiophot2 fluorescent microscope (Carl Zeiss AG, Jena, Germany).
Animals. Male R6/2 mice were bred with females from their background strain (B6CBAFI/J), and offspring were genotyped using PCR. 5, 17 CAG repeat length remained stable within a 147-153 range. Female mice were used in the experimental paradigms.
Quantitative real time-PCR (qRT-PCR). qRT-PCR was performed as previously described. 5 The primer sequences for ATRX gene expression as follow: forward, 5 0 -CAGAGAAATGTAGACCCAGA-3 0 ; reverse, 5 0 -GGTTATCAGTAG CACAGTCA-3 0 . The primer sequences for ChIP-qPCR of ATRX promoter was as follow: forward, 5 0 -AGGATCTGTGTAGTGGTCGA-3 0 ; reverse, 5 0 -CTGCTG ACCTCAAAGTGTCA-3 0 .
Chromatin immunoprecipitation (ChIP). ChIP for Cdx2, Sp1, and Sp3 binding to DNA was performed using a ChIP assay kit (Santa Cruz Biotech, Santa Cruz, CA, USA) as previously described. 28 Tissues and cells were crossed-linked with 1% formaldehyde for 20 min at room temperature. The lysates were sonicated six times with each time for 30 s using Bioruptor (Diogenode, Denville, NJ, USA). After centrifugation, the supernatant was diluted in ChIP dilution buffer and then incubated overnight at 4 1C with the primary antibody. The eluted DNA was quantified by qPCR and normalized to IgG control.
Confocal microscopy. Immunofluorescence staining and confocal microscopy was used to determine the ATRX (H-300: sc-15408) (Santa Cruz Biotech; 1 : 200), Cdx2 (AB4123) (Chemicon, Billerica, MA, USA; 1 : 200), PML (36-1-104: K0196-3) (MBL, Woburn, MA, USA; 1 : 1000), and trimethyl-Histone H3 (Lys9) (07-442) (Upstate Biotech, Bridgewater, NJ, USA; 1 : 1000) as previously described. 5 Images were analyzed using a spinning disk confocal microscope (Olympus DSU, Tokyo, Japan). Deconvolution and 3-dimentainal construction of the confocal image were performed by AQI-X-COMBO-CWF program (Media cybernetics Inc., Bethesda, MD, USA). Control experiments were performed in the absence of primary antibody or in the presence of blocking peptide.
ATRX promoter activity analysis. ATRX-promoter analysis was performed using a reporter-construct containing 5 0 regulatory region of the human ATRX gene (À548/ þ 101) including nested deletion constructs (À438/ þ 101; À248/ þ 101). The site-directed mutagenesis was used to generate a mutant reporter with the deletion of Cdx-binding element (Stratagene, Santa Clara, CA, USA). Cells (SH-SY5Y) were transiently transfected with ATRX promoters in the presence or the absence of transcription factors. The luciferase activity was measured 48 h after the transfection. The promoter activity was normalized to protein concentrations. 
